newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicati